Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Yates

Nurse Practitioner, Gerontology Rochester, NY Nurse Practitioner

NPI 1407321953 CMS profile 10852299

500 Helendale Rd # L20, Ste 440, Rochester, NY 14609

Open in the dashboard

General payments

$22,694

181 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Yates of Rochester, NY is reported in the CMS Open Payments database as having received $22,694 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,992 33
2024 General $7,382 34
2023 General $2,431 39
2022 General $7,714 53
2021 General $1,174 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Yates
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Amy Yates were reported at $3,992. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Amy Yates Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,174 $133 $44–$396 $132
2022 $7,714 $142 $48–$452 $149
2023 $2,431 $158 $53–$482 $160
2024 $7,382 $171 $55–$533 $164
2025 $3,992 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $16,499 115 payments
  2. Medtronic, Inc. $2,113 29 payments
  3. Nalu Medical, Inc. $1,417 9 payments
  4. Saluda Medical Americas, Inc. $1,185 4 payments
  5. Nevro Corp. $599 8 payments
  6. SPR Therapeutics, Inc $205 3 payments
  7. Globus Medical, Inc. $193 3 payments
  8. Averitas Pharma Inc. $183 3 payments
  9. Spinal Simplicity, LLC $89 1 payment
  10. Vertos Medical, Inc. $85 1 payment
  11. Other $125 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,135 126 payments
  2. Travel and Lodging $5,423 28 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,463 9 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $3,730 10 payments
  5. Consulting Fee $1,863 5 payments
  6. Education $81 3 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $10,159 44 payments
  2. AXIUM $2,246 12 payments
  3. PROCLAIM Neuromodulation $1,657 11 payments
  4. SYNCHROMEDII $1,500 21 payments
  5. Nalu Neurostimulation System $1,417 9 payments
  6. Evoke $1,185 4 payments
  7. PROCLAIM Structural Heart $518 6 payments
  8. INTELLIS ADAPTIVESTIM $496 5 payments
  9. Proclaim IPG $430 6 payments
  10. Omnia $403 5 payments
  11. Other $2,682 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,014

Median for Nurse Practitioner: 389

Drug cost

$44,703

Median for Nurse Practitioner: $21,885

Branded share of claims

8.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucynta Tapentadol Hcl Brand 11 $13,831
Pregabalin Generic 177 $8,675
Celecoxib Generic 59 $4,461
Buprenorphine Generic 16 $3,987
Gabapentin Generic 218 $3,124
Duloxetine Hcl Generic 64 $2,816
Naloxone Hcl Generic 26 $1,684
Baclofen Generic 90 $1,089
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 56 $1,054
Lidocaine Generic 18 $914

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$12,515

Medicare's payments for the services billed

Medicare patients

89

Average age 66

Services billed

277

57 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 65%
Depression 47%
Diabetes 29%
Ischemic heart disease 26%
COPD 21%
Heart failure 18%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Fintepla
  • UCB, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record